Quick Answer
Humira (adalimumab) can cost roughly $7,000–$13,000 per month without insurance, depending on the pharmacy and product. As of 2026, more than 10 FDA-approved adalimumab biosimilars are on the market, with cash prices as low as $550/month for some options — a discount of 50–95% off Humira's list price. Several of these biosimilars carry the FDA's "interchangeable" designation, meaning a pharmacist may be able to substitute them for Humira without a new prescription, similar to how a generic works.
What Is Humira Used For?
Humira is a biologic medication that blocks tumor necrosis factor (TNF), a protein that drives inflammation. It's prescribed for chronic inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn's disease, and ulcerative colitis. It's typically self-injected under the skin, often every other week.
Why There's No "Generic" Humira
Humira is a biologic — made from living cells, not synthesized chemically like a typical pill. Because of that manufacturing complexity, it's not possible to create an exact chemical copy the way a generic tablet copies a brand-name pill. Instead, the FDA approves biosimilars: products shown to have no clinically meaningful differences from the original biologic in safety, purity, or potency.
Some biosimilars go a step further and earn an interchangeable designation, meaning the FDA has additional data supporting that switching between the biosimilar and Humira (or between the biosimilar and another interchangeable product) doesn't reduce safety or effectiveness. In most states, an interchangeable biosimilar can be substituted at the pharmacy without requiring a new prescription — much like a generic swap.
How Much Can You Actually Save?
Pricing varies significantly by product, pharmacy, and whether you're paying cash or through insurance:
- Humira (brand): List price around $6,900–$7,000 for a one-month supply of standard pens; cash prices at retail pharmacies can run $7,000–$13,000+ depending on the pharmacy and discount program.
- Adalimumab biosimilars: Cash prices ranging from roughly $550 to a few thousand dollars per month, depending on the specific product and whether it's sold at a standard or "low list price" tier.
- Typical discount range: Most biosimilars are priced 50–80% below Humira's list price; some ultra-low-price versions have launched at discounts of 90%+ .
Because pricing shifts as more biosimilars enter the market and negotiate with insurers, treat these as general ranges rather than fixed numbers — always confirm current pricing with your pharmacy or insurance plan.
Interchangeable Adalimumab Biosimilars (as of 2026)
Several adalimumab biosimilars carry the FDA's interchangeable designation, including Amjevita, Cyltezo, Hadlima, Hyrimoz, Hulio, Simlandi, Yuflyma, and Abrilada. This list continues to grow as more products earn interchangeable status — ask your pharmacist which options are currently available and interchangeable in your state, since state pharmacy substitution laws vary.
What to Ask Before Switching
- Is the biosimilar interchangeable, or does it need a new prescription? Non-interchangeable biosimilars still require your doctor to write a new prescription rather than an automatic pharmacy swap.
- Does the concentration/formulation match what you're used to? Some products come in citrate-free or higher-concentration formulations that affect injection comfort and volume — not just the active ingredient.
- What does your insurance actually cover? Formularies often favor a specific biosimilar; the cheapest cash price isn't always the cheapest option under your specific plan.
- Is there a patient assistance program available? Both the Humira manufacturer and biosimilar makers often run copay assistance or patient assistance programs for eligible patients.
Medicare and Adalimumab
For provider-administered adalimumab under Medicare Part B, billing uses a specific HCPCS code, and reimbursement is generally based on average sales price plus a set percentage. If adalimumab is self-injected at home and covered under your Part D plan instead, the 2026 Part D out-of-pocket cap (see our Medicare Part D guide) may apply to your share of the cost.
Bottom Line
If you're currently on brand-name Humira and haven't discussed biosimilars with your doctor or pharmacist, it's worth asking. With more than 10 FDA-approved options now available — several of them interchangeable — there's a meaningful chance you can stay on essentially the same medication at a significantly lower cost.
[DRAFT STATUS: Ready for pharmacist review. Pricing figures are approximate and change frequently as new biosimilars launch and negotiate formulary placement — reverify current prices and the interchangeable-product list against the FDA Purple Book before publishing.]
